LONDON – Newco Northsea Therapeutics BV has sailed onto the scene with a portfolio of structurally engineered fatty acids and a €25 million (US$29.4 million) series A funding round to take the lead product, icosabutate (PRC-4016), through phase IIb in the treatment of nonalcoholic steatohepatitis (NASH).